Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-22 4:06 pm Purchase | 13D | Freeline Therapeutics Holdings plc FRLN | Syncona Portfolio Ltd | 65,872,764 100.000% | 28,010,632 (+73.98%) | View |
| 2024-02-14 12:15 pm Unchanged | 13G | Freeline Therapeutics Holdings plc FRLN | EVENTIDE ASSET MANAGEMENT LLC | 0 0.000% | 0 (Unchanged) | View |
| 2024-02-12 4:24 pm Sale | 13G | Freeline Therapeutics Holdings plc FRLN | INTEGRATED CORE STRATEGIES (US) LLC | 0 0.000% | -5,555,085 (Position Closed) | View |
| 2024-01-31 4:10 pm Purchase | 13G | Freeline Therapeutics Holdings plc FRLN | Tetragon Financial Management LP | 6,375,000 9.800% | 6,375,000 (New Position) | View |
| 2023-11-24 07:30 am Unchanged | 13D | Freeline Therapeutics Holdings plc FRLN | Syncona Portfolio Ltd | 37,862,132 57.900% | 0 (Unchanged) | View |
| 2023-10-18 06:04 am Purchase | 13D | Freeline Therapeutics Holdings plc FRLN | Syncona Portfolio Ltd | 37,862,132 57.920% | 37,862,132 (New Position) | View |
| 2023-07-17 4:50 pm Purchase | 13G | Freeline Therapeutics Holdings plc FRLN | INTEGRATED CORE STRATEGIES (US) LLC | 5,555,085 8.500% | 5,555,085 (New Position) | View |
| 2023-02-14 1:54 pm Purchase | 13G | Freeline Therapeutics Holdings plc FRLN | EVENTIDE ASSET MANAGEMENT LLC | 5,920,765 9.100% | 2,435,109 (+69.86%) | View |
| 2023-02-13 12:01 pm Purchase | 13G | Freeline Therapeutics Holdings plc FRLN | CHI Advisors LLC | 4,814,419 7.410% | 2,938,030 (+156.58%) | View |
| 2023-01-31 4:15 pm Purchase | 13G | Freeline Therapeutics Holdings plc FRLN | Tetragon Financial Management LP | 4,000,000 6.200% | 300,000 (+8.11%) | View |
| 2022-03-25 4:07 pm Purchase | 13D | Freeline Therapeutics Holdings plc FRLN | Syncona Portfolio Ltd | 37,862,147 62.270% | 19,047,620 (+101.24%) | View |
| 2022-03-21 11:10 am Purchase | 13G | Freeline Therapeutics Holdings plc FRLN | Tetragon Financial Management LP | 3,700,000 6.100% | 3,700,000 (New Position) | View |
| 2022-02-14 11:47 am Purchase | 13G | Freeline Therapeutics Holdings plc FRLN | EVENTIDE ASSET MANAGEMENT LLC | 3,485,656 9.700% | 1,000,000 (+40.23%) | View |
| 2022-02-11 1:00 pm Purchase | 13G | Freeline Therapeutics Holdings plc FRLN | CHI Advisors LLC | 1,876,389 5.240% | 1,876,389 (New Position) | View |
| 2022-02-11 12:20 pm Unchanged | 13G | Freeline Therapeutics Holdings plc FRLN | Syncona Portfolio Ltd | 18,814,527 52.500% | 0 (Unchanged) | View |
| 2022-02-04 09:06 am Sale | 13G | Freeline Therapeutics Holdings plc FRLN | WELLINGTON MANAGEMENT GROUP LLP | 439,795 1.230% | -1,374,189 (-75.76%) | View |
| 2021-11-02 4:32 pm Sale | 13G | Freeline Therapeutics Holdings plc FRLN | Novo Holdings A/S | 1,785,563 4.990% | -575,666 (-24.38%) | View |
| 2021-08-10 07:57 am Sale | 13G | Freeline Therapeutics Holdings plc FRLN | WELLINGTON MANAGEMENT GROUP LLP | 1,813,984 5.060% | -1,707,602 (-48.49%) | View |
| 2021-02-12 4:07 pm Purchase | 13G | Freeline Therapeutics Holdings plc FRLN | EVENTIDE ASSET MANAGEMENT LLC | 2,485,656 7.500% | 2,485,656 (New Position) | View |
| 2021-02-12 11:04 am Purchase | 13G | Freeline Therapeutics Holdings plc FRLN | Syncona Portfolio Ltd | 18,814,527 54.200% | 18,814,527 (New Position) | View |